CDH2 and keloid: Furthermore, treatment of keloid fibroblasts with the IL-6 receptor inhibitor, tocilizumab, decreased N-cadherin puncta (Fig. 5E), while IL-6 treatment of normal fibroblasts increased puncta (Fig. 5F), indicating that intercellular adhesion development is downstream of IL-6 signaling.